[Hypolipidemic effect of sulfated polysaccharides]

Area of Science:

• Biochemistry
• Pharmacology
• Biomaterials Science

Background:

• Hyperlipidemia is a major risk factor for cardiovascular diseases.
• Current treatments for hyperlipidemia have limitations and side effects.
• Novel therapeutic agents are needed to manage lipid disorders effectively.

Purpose of the Study:

• To investigate the hypolipidemic effects of novel sulfated polysaccharides.
• To evaluate the impact of chitosan, lutelan, and krilan sulfates on lipid profiles in hyperlipidemic rats.
• To determine the optimal molecular mass and sulfation rate for maximal efficacy.

Main Methods:

• Induction of hyperlipidemia in a rat model.
• Administration of varying doses of sulfated polysaccharides (chitosan, lutelan, krilan sulfates).
• Analysis of serum lipid profiles, including VLDL and HDL cholesterol levels.

Main Results:

• Sulfated polysaccharides exhibited a significant hypolipidemic effect.
• Treatment led to a pronounced decrease in very-low-density lipoprotein (VLDL) levels.
• A notable increase in high-density lipoprotein (HDL) levels was observed.
• Optimal efficacy was achieved with molecular mass of 20-40 x 10(3) D and sulfation rate of 9-14%.

Conclusions:

• Novel sulfated polysaccharides show promise as therapeutic agents for hyperlipidemia.
• Chitosan, lutelan, and krilan sulfates can effectively modulate lipid profiles.
• Specific molecular mass and sulfation rates enhance the hypolipidemic activity of these compounds.